

BioInnovation
Institute

BII is a non-profit foundation funded with 470M EUR from the Novo Nordisk Foundation

BII

**ново
нордиск
фонден**

Scientific research
Diabetes treatment
Innovation
Education & outreach
Humanitarian and social causes

**USD
856M**
Grants
awarded
in 2017

Dividend

100% SHARES

USD 51B AUM

**ново
holdings**
Investors in life science

Principal investments
Venture investments
Seed investments
Financial investments


**USD
3.1B**
Investment
result in
2017


28.1% SHARES
75.5% VOTES

25.5% SHARES
71.2% VOTES



BII is different from The Novo Foundation and Novo Holding - both in terms of focus area and funding type.





BII helps start-ups become **investment ready** by bridging the gap between **academia** and **business**.

Therapeutics



Bioindustrials



Health tech



WHO is BII for?

BII's programs are for early life science **entrepreneurs** and established **organizations** who want to support the life science ecosystem.

BII is primarily engaged with start-ups and partners within **three key areas** of the life science industry.



Knowledge

Network



Funding

Infrastructure

We select promising start-ups and support them by offering **four essentials** for success.



Every BII start-up gets their own BII anchor: an expert responsible for supporting their business development with **knowledge**, tools and mentorship.



Our start-ups benefit from our **network** within the eco-system. Our collaboration partners take a starting point in the start-up's journey and needs.



Faculty

Grant

36 months

Up to
EUR 2.5M

Venture Lab

Convertible loan

12 months

Up to
EUR 1/2M



Creation House

Convertible loan

18 months

Up to
EUR 1.3M

Our start-ups get access to **funding** via our programs to help them accelerate their business.




Our start-ups get access to our community and **Infrastructure** which includes office space, laboratory facilities and technical platforms.


**Selection
process**



Application process - BII shares the due diligence reports with shortlisted applicants



Application process - Invited applicants pitch to Europe's top Investors




Being a part of BII



The Venture Lab Program provides the tools for entrepreneurs


Crunches to build a business plan

Kick-off bootcamp




Demoday

Halos to deal with psychological challenges as founders

















BII Partners

Helping us bring research to market






























BII has a **diverse portfolio** of promising start-ups within BioIndustrials.

 Fundraising
 Alumni

	Proof of Concept Stage	Optimization Stage	Application Stage	Scaling Stage	Commercial stage
BioIndustrials					
Materials					
Carbon Capture					
Animal Health					
Food and Beverages					
Platform technology					
Aqua culture					
Ag-Tech					

BII has a diverse portfolio of promising start-ups within Therapeutics.

 Fundraising
 Alumni

	Hits	Lead Optimization	Lead Candidate	Toxicology	Clinic
Therapeutics					
Oncology	 	 			
CNS					
Metabolism	 		 		
Antiviral					
Platform technology	  				
Reproductive Health		 			

An international portfolio



Liver implant

Stimuliver is developing a liver implant which uses lab engineered liver tissue that will be placed underneath the skin to 'top up' the patient's reduced liver function. Liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue.



BOOST Pharma

Treating the untreatable



Cell therapy treatments for
Osteogenesis Imperfecta.

In vitro expanded mesenchymal stem
cells to treat severe Osteogenesis
Imperfecta (OI) or Brittle Bone Disease
in children and unborn babies

CIROLE

biomedical

BII BioInnovation
Institute

 Rhia
VENTURES



Non-hormonal contraceptive



Mucus engineering for novel
non-hormonal contraceptive

Remote Parkinson's disease monitoring

ÖRBIT

Device agnostic, AI-powered solution for the personalization of treatment of Parkinson's patients through continuous and objective remote disease state monitoring.



Total BII
(excl. Faculty)

66

start-ups
from 2018-2021

38

Start-ups
received
external funding

3

Series A
investments
> 10M EUR

6

Seed
investments
> 1M EUR


17

Minor
investments
< 1M EUR


76

Additional
grants

Granted funding by BII vs. granted external funding
(accumulated)



Split between loans, grants and investments



58%

of portfolio have raised
external funding since 2018

147M

EUR raised in external funding
by our portfolio

3.2x

external funding leverage in
average across portfolio

23%

Of start-ups in Creation House
were also part of Venture Lab



TWELVE BIO
MEDICAL

Lopinor
ANKRIN

Next application deadline:

Venture Lab

24th February, 2022

Scan to read more:

